Abstract:Activation of the p53 tumor suppressor can lead to cell cycle arrest. The key mechanism of p53-mediated arrest is transcriptional downregulation of many cell cycle genes. In recent years it has become evident that p53-dependent repression is controlled by the p53–p21–DREAM–E2F/CHR pathway (p53–DREAM pathway). DREAM is a transcriptional repressor that binds to E2F or CHR promoter sites. Gene regulation and deregulation by DREAM shares many mechanistic characteristics with the retinoblastoma pRB tumor suppressor that acts through E2F elements. However, because of its binding to E2F and CHR elements, DREAM regulates a larger set of target genes leading to regulatory functions distinct from pRB/E2F. The p53–DREAM pathway controls more than 250 mostly cell cycle-associated genes. The functional spectrum of these pathway targets spans from the G1 phase to the end of mitosis. Consequently, through downregulating the expression of gene products which are essential for progression through the cell cycle, the p53–DREAM pathway participates in the control of all checkpoints from DNA synthesis to cytokinesis including G1/S, G2/M and spindle assembly checkpoints. Therefore, defects in the p53–DREAM pathway contribute to a general loss of checkpoint control. Furthermore, deregulation of DREAM target genes promotes chromosomal instability and aneuploidy of cancer cells. Also, DREAM regulation is abrogated by the human papilloma virus HPV E7 protein linking the p53–DREAM pathway to carcinogenesis by HPV. Another feature of the pathway is that it downregulates many genes involved in DNA repair and telomere maintenance as well as Fanconi anemia. Importantly, when DREAM function is lost, CDK inhibitor drugs employed in cancer treatment such as Palbociclib, Abemaciclib and Ribociclib can compensate for defects in early steps in the pathway upstream from cyclin/CDK complexes. In summary, the p53–p21–DREAM–E2F/CHR pathway controls a plethora of cell cycle genes, can contribute to cell cycle arrest and is a target for cancer therapy.

DREAM On: Cell Cycle Control in Development and Disease

Evolutionarily Conserved Multisubunit RBL2/p130 and E2F4 Protein Complex Represses Human Cell Cycle-Dependent Genes in Quiescence.

Structure and function of MuvB complexes

Comprehensive Analysis of the Expression and Prognosis for the DREAM Complex in Human Cancers

Long noncoding RNA DREAMer bridges the DREAM complex and E2f1 to regulate endoreplication in Drosophila

Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM

A dual transcriptional reporter and CDK-activity sensor marks cell cycle entry and progression in C. elegans

Canonical and Atypical E2Fs Regulate the Mammalian Endocycle

In my end is my beginning: control of end resection and DSBR pathway ‘choice’ by cyclin-dependent kinases

Bam-Dependent Deubiquitinase Complex Can Disrupt Germ-Line Stem Cell Maintenance By Targeting Cyclin A

Transcriptional repression and enhancer decommissioning silence cell cycle genes in postmitotic tissues

Cell cycle regulation and neural differentiation

The molecular circadian rhythms regulating the cell cycle

HDAC activity is dispensable for repression of cell-cycle genes by DREAM and E2F:RB complexes

Geminin Coordinates Cell Cycle and Developmental Control.

Cell Cycle Regulation by Micrornas in Stem Cells

Translational regulation of the cell cycle: when, where, how and why?

Cell cycle regulation: p53-p21-RB signaling

Evolutionarily recent transcription factors partake in human cell cycle regulation

Chromodomain Helicase DNA-Binding Proteins in Stem Cells and Human Developmental Diseases